Avastin/Tarceva combo does not improve survival
Genentech and OSI Pharmaceuticals have announced the combination treatment of Avastin (bevacizumab) with Tarceva (erlotinib) has not shown to improve survival in a Phase III study. - News - PharmaTimes
by Katrina Megget
https://www.pharmatimes.com/news/avastintarceva_combo_does_not_improve_survival_986661